Akoya, Acrivon to develop CDx for cancer treatment

2019 11 04 21 37 0904 Ovarian Cancer 400

Akoya Biosciences and Acrivon Therapeutics plan to partner on developing, validating, and marketing Acrivon's OncoSignature test.

OncoSignature identifies cancer patients likely to respond to treatment with ACR-368, a targeted DNA damage response inhibitor therapy that Acrivon is developing.

The U.S. Food and Drug Administration (FDA) has cleared OncoSignature to be used in a phase 2 trial for treating patients with ovarian, endometrial, and urothelial cancer "based on predicted sensitivity to ACR-368," the companies said.

Page 1 of 16
Next Page